Background: The American Dental Association conducted the 2000 Membership Needs and Opinions Survey to evaluate the professional needs and personal perceptions of ADA members on selected topics.
Methods: A questionnaire was sent to a sample of 6,310 ADA members in January 2000 with follow-up mailings in February, March and April 2000. Data collection was completed in July 2000. The survey included questions on critical professional issues, perceptions of the American Dental Association and its priorities. A total of 3,558 surveys were received for an adjusted response rate of 59.5 percent. Only professionally active dentists who were ADA members were included in the sampling frame.
Results: Members evaluated statements about the American Dental Association, revealing their perceptions of the ADA on key issues. Findings showed strong support for the ADA Seal program, agreement that the ADA enhances the integrity and ethics of the profession and that the ADA is the premier professional association for dentists. Findings also provided information regarding the relative importance of ADA priorities by allocating "dues dollars" in $5 increments. The highest priorities were "providing continuing education to dentists," "lobbying members of Congress and federal regulatory agencies" and "influencing national public health policy."
Conclusions: ADA members, both new and established dentists, had positive perceptions of the Association and its programs. Although there was general agreement between these groups concerning ADA priorities, there was a substantial difference between some subgroups (especially graduate students and federally employed dentists) and the overall membership on the issue of changes in the licensure process to facilitate dentists' freedom of movement.
Practice Implications: The Association should continue to take into account the membership's perceptions of the ADA and its priorities, as well as note issues of special interest to selected membership subgroups, in the planning and implementation of Association activities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14219/jada.archive.2003.0136 | DOI Listing |
Front Pharmacol
January 2025
Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States.
Introduction: TNFα inhibitor (TNFi) immunogenicity in rheumatoid arthritis (RA) is a major obstacle to its therapeutic effectiveness. Although methotrexate (MTX) can mitigate TNFi immunogenicity, its adverse effects necessitate alternative strategies. Targeting nuclear factor of activated T cells (NFAT) transcription factors may protect against biologic immunogenicity.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
January 2025
Université de Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France; Department of Metabolism, Imperial College London, London, UK. Electronic address:
Diabetes is a leading cause of global mortality and disability, and its economic burden is substantial. This Review focuses on type 2 diabetes, which makes up 90-95% of all diabetes cases. Type 2 diabetes involves a progressive loss of insulin secretion often alongside insulin resistance and metabolic syndrome.
View Article and Find Full Text PDFAm J Clin Nutr
January 2025
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Global Health Graduate Program, McMaster University, Hamilton, ON, Canada; Population Health Research Institute, Hamilton, ON, Canada.
Aust Prescr
December 2024
Sydney Dental School, Faculty of Medicine and Health, The University of Sydney.
Front Immunol
January 2025
Polpharma Biologics S.A., Gdansk, Poland.
Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in healthy subjects and patients with relapsing-remitting MS (RRMS) to confirm a matching immunogenicity profile between biosim-NTZ and ref-NTZ.
Methods: Immunogenicity of biosim-NTZ versus ref-NTZ was evaluated in two pivotal clinical studies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!